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Recipients of hematopoietic stem cell transplantation (HSCT) frequently have iron overload resulting from chronic transfusion
therapy for anemia. In some cases, for example, in patients with myelodysplastic syndromes and thalassemia, this can be further
exacerbated by increased absorption of iron from the gut as a result of ineﬀective erythropoiesis. Accumulating evidence has
established the negative impact of elevated pretransplantation serum ferritin, a surrogate marker of iron overload, on overall
survival and nonrelapse mortality after HSCT. Complications of HSCT associated with iron overload include increased bacterial
and fungal infections as well as sinusoidal obstruction syndrome and possibly other regimen-related toxicities. Based on current
evidence, particular attention should be paid to prevention and management of iron overload in allogeneic HSCT candidates,
especially in patients with thalassemia and myelodysplastic syndromes. The pathophysiology of iron overload in the HSCT patient
and optimum strategies to deal with iron overload during and after HSCT require further study.
1.Introduction
Hematopoietic stem cell transplantation (HSCT) is increas-
ingly used as curative therapy for a variety of disorders of the
hematopoietic and immune systems. Although considerable
advances in transplantation practice have resulted in greater
overall survival rates, transplant-related mortality is a major
hurdle to improving HSCT outcome, especially in older
patients and those who are transplanted in the later stages
of their hematologic disorder. Transplantation outcomes
can vary greatly among diseases and are impacted by a
range of complications such as infections, graft-versus-host
disease (GVHD), and toxicities related to the conditioning
regimen, including hepatic sinusoidal obstruction syndrome
(SOS) [1]. Iron overload is a common problem in red cell
transfusion-dependent patients who undergo HSCT. The
strongest evidence for the adverse impact of iron overload
on HSCT outcome comes from the thalassemia literature
[2]. In recent years, the role of iron overload as a risk factor
in nonthalassemic HSCT transplant recipients has also been
widely investigated due to its potential impact on patient
morbidity and mortality. This paper discusses the current
literature on iron overload as it pertains to the HSCT patient
and outlines areas for future research.
2. Iron Overloadin the HSCTPatient
Iron overload, as measured by pre-transplantation serum
ferritin, is common in recipients of HSCT, particularly
in those with hemoglobinopathies, acute leukemia, and
myelodysplastic syndromes (MDSs) (Figure 1). Red blood
cell transfusion therapy as supportive care for chronic
anemia is the principal cause of iron overload in such
patients. Patients may also require further transfusion ther-
apyfollowingconditioningandpriortoengraftment.Aseach
unit of transfused packed red cells contains approximately
200–250mg of iron, patients who are administered regular
transfusions can receive a daily iron excess of up to 0.5mg/kg
[3]. With no physiologic mechanism for clearing excess iron2 Advances in Hematology
taken in as a result of transfusions, iron accumulation is an
inevitable sequel, and patients can become iron overloaded
after as few as 10–20 transfusions [4]. In some patients,
such as those with MDS and thalassemia, the underlying
conditions for which they are being treated may cause
them to have excessive iron absorption from the gut as
a consequence of ineﬀective erythropoiesis. This eﬀect is
mediated by erythroid regulators of iron metabolism, which
suppress hepcidin and, in turn, result in increased iron
absorption from the duodenum.
3.Pathophysiology ofIronOverload
As iron can readily donate and accept electrons, intercon-
verting between ferrous (Fe2+) and ferric (Fe3+)f o r m s ,i t
is an important component of various cytochromes and
is required for the functioning of a number of enzymes.
However, this property also makes iron highly toxic, being
able to catalyze the conversion of hydrogen peroxide into
free-hydroxyl radical ions that can damage cellular mem-
branes, proteins, and DNA [5]. Under normal conditions,
the potential toxicity of plasma iron is eliminated by seques-
tration into complexes with transferrin, the major plasma
iron-binding protein. However, the presence of excess body
iron can quickly saturate the available transferrin and result
in the appearance of nontransferrin-bound iron (NTBI).
The pathologically relevant component of NTBI is labile
plasma iron (LPI), which encompasses organ-penetrating
forms of iron that are redox active and directly chelatable
[6]. Generation of LPI leads to unregulated iron uptake
and subsequent intracellular storage either within ferritin
molecules or as hemosiderin, an iron storage complex.
When the sequestering capacity of iron-binding proteins is
exceeded, excessive labile iron pools develop, which are the
mediators of organ toxicity in iron-overloaded patients [7].
In the absence of treatment the toxic eﬀects of the stored
iron will result in ongoing tissue damage and ultimately
organ dysfunction and failure [4]. Therefore, the adverse
consequences of iron overload can arise from the elevation
of NTBI and LPI in plasma, as well as due to organ
damagemediatedbytheaccumulationoftissueironintarget
organs. The sources of elevated NTBI in HSCT patients are
summarized in Table 1.
Iron from red cell transfusions initially accumulates
bound to ferritin in the macrophages of tissues such as liver,
spleen, and bone marrow. Iron export into plasma from
i r o n - l o a d e dm a c r o p h a g e sa sw e l la sd u o d e n a le n t e r o c yt e s( i n
the case dietary iron absorption) occurs via the iron export
protein ferroportin located on the membrane of these cells
[9]. Ferroportin expression in turn is negatively regulated
by hepatic production of hepcidin, a key hormone that
regulates iron metabolism by inducing the internalization
and degradation of ferroportin [10]. Serum hepcidin-25
levelshavebeenshowntonegativelycorrelatewiththedegree
of erythropoiesis in the HSCT setting [11]. Thus, the degree
of erythropoietic activity after HSCT appears to be the major
regulator of hepcidin level which in turn may determine
plasma iron levels in the HSCT setting.
Table 1: Causes of increased NTBI in HSCT recipients.
Source of iron Underlying mechanism
Increased intestinal iron
absorption due to low
hepcidin
(i) Feature of some chronic
anemias (e.g., MDS,
thalassemia intermedia)
(ii) HFE gene mutations
Increased macrophage iron (i) Red cell transfusion
therapy
Under utilization of plasma
iron
(i) Inhibition of
erythropoiesis as a result of
cytotoxic therapy used as
part of the conditioning
regimen
Release of cellular iron
(i) Destruction of bone
marrow and tumor cells as
a result of cytotoxic therapy
used as part of the
conditioning regimen
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Figure 1: Iron overload in patients undergoing HSCT [8]. Dots
represent individual patients, thick grey lines show median values,
and the boxes indicate interquartile range. Horizontal black line
represents a serum ferritin level of 1000ng/mL. CML: chronic
myeloid leukemia; MPD: myeloproliferative disorder [8].
The conditioning regimen itself can also contribute to
the increase in NTBI levels, partly due to inhibition of
erythropoiesis, the main route of iron utilization. In one
study, NTBI peaked as early as 4 days prior to transplan-
tation, and was detectable for 6–18 days in all patients
[12]( Figure 2). Other studies have shown similar results
[13, 14]. In addition, stored iron can be released from
the liver as a result of tissue injury that can occur during
conditioning [12, 15, 16]. Transferrin levels can drop as an
acute phase reaction, and transferrin saturation can increase
during chemoradiotherapy, often reaching indexes of more
than80%andleadingtoincreasedlevelsofNTBI[12,13,16].Advances in Hematology 3
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Figure 2: Mean ± SD serum level of the calculated transferrin sat-
uration in 10 allogenic SCT patients during the peritransplantation
period. Arrow indicates onset of the conditioning regimen [12].
Conditions in the peritransplantation period can therefore
result in elevated NTBI and LPI levels in the plasma, which
persist at least until engraftment.
Normally, endogenous antioxidants also play a role in
scavenging free radicals and preventing cell damage [17].
However, in patients undergoing HSCT, chemotherapy or
radiotherapy-based conditioning regimens can result in a
prooxidant status, as indicated by a reduced total radi-
cal antioxidant parameter of plasma (TRAP), a measure
of the overall capacity of human plasma to inhibit free
radical-induced lipid peroxidation [14, 18]. In one study,
assessment of the antioxidant status before and after HSCT
showed a breakdown in plasma antioxidant defense and
an inverse correlation between levels of NTBI and TRAP.
Recent data have also demonstrated a prooxidant state in
patients conditioned with chemoradiotherapy, indicated by
signiﬁcant increases in malondialdehyde (an indicator of
oxidative stress and lipid peroxidation), glutathione perox-
idase, and super oxide dismutase [19]. Decreased levels of
other endogenous antioxidants such as α-tocopherol and β-
carotene have also been noted [14, 20]. The disturbance of
pro-oxidative/antioxidative balance in the plasma of patients
undergoing HSCT may augment the toxicity of LPI and
suggests that the adminstration of antioxidants, such as N-
acetylcysteine or glutamine (glutathione precursor), may,
therefore, be beneﬁcial [14].
In addition to performing a vital role in the human
body, iron is an important element for the growth of
pathogenicmicroorganisms[21,22].Highplasmaironlevels
can therefore not only promote microbial growth but can
also directly increase susceptibility to infection by inhibiting
the function of the immune system. High intracellular iron
levels have been shown to result in the direct impairment of
innate and acquired immune responses [21].
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Figure 3: Prognostic impact of elevated pre-transplantation serum
ferritin in patients undergoing myeloablative stem-cell transplanta-
tion (N = 190). Dashed line represents patients with serum ferritin
over 1000ng/ml. Adapted from [8].
4. Impact of High Pretransplantation
SerumFerritinLevelsonSurvivaland
Complications
The adverse impact of iron overload on HSCT outcome
was ﬁrst demonstrated in thalassemia patients. In fact, the
degree of iron overload and adequacy of chelation is used for
prognostic classiﬁcation of thalassemia patients undergoing
allogeneic HSCT. Multivariate analysis has identiﬁed three
iron-related factors associated with a signiﬁcantly reduced
probability of survival: hepatomegaly, hepatic portal ﬁbrosis,
and inadequate iron chelation [23]. Patients with none of
these pre-HSCT risk factors are considered low risk (Class
1), those with one or two are moderate risk (Class 2), and
those with all three risk factors are high risk (Class 3). While
the probability of long-term survival after HSCT in Class 1
patients may be more than 90%, survival can be anticipated
in only around 50% of high risk, Class 3, patients [2, 23].
In recent years, a number of studies have investigated
the eﬀect of high pre-transplantation serum ferritin levels
on survival after HSCT in nonthalassemic patients (Table 2).
Although most of the studies are retrospective, the results
are unequivocal; the increased incidence of complications
associated with high iron load results in reduced overall
survival after HSCT particularly in patients with MDS and
acute leukemia (Figure 3)[ 8, 24–31]. This is true for both
full- and reduced-intensity conditioning regimens for HSCT
suggesting that reduction in conditioning intensity alone
may not be adequate to minimize the deleterious eﬀects of
iron overload on survival.
Conditioning regimens, cytopenias, and the use of
immunosuppressive agents can result in severely compro-
mised immunity. As a consequence, infection accounts
for much of the treatment-related mortality observed
in HSCT patients. A recent prospective evaluation of
190HSCT patients has conﬁrmed that serum ferritin values
of ≥1000ng/mL are associated with a signiﬁcant increase
in the incidence of blood stream infections [8]. In this
study, patients with pretransplantation serum ferritin above
1000ng/ml had a twofold increased risk of developing blood4 Advances in Hematology
Table 2: Published data showing the impact of pretransplantation serum ferritin levels on survival in HSCT recipients.
Patient type and
number Type of HSCT Outcome measures Key results
Armand et al.
2007 [24]
590 patients with a
variety of disorders
(primarily CML,
AML, or MDS)
Allogeneic
(myeloablative)
Retrospective
evaluation of 5-year
overall survival,
treatment-related
mortality, disease-free
survival and relapse
(i) Elevated pre-transplantation serum
ferritin strongly associated with lower
overall- and disease-free survival
(ii) Subgroup analysis showed
association restricted to patients with
AML or MDS
Mahindra et al.
2008 [25]
315 Hodgkin or
nonHodgkin
lymphoma patients
Autologous
Retrospective
evaluation of 6-year
o v e r a l ls u r v i v a la n d
relapse mortality
(i) Pre-transplantation serum ferritin
levels of >685ng/mL associated with
signiﬁcantly lower overall and
relapse-free survival (P = .002 and .021,
resp.)
Pullarkat et al.
2008 [8]
190 patients with
lymphoma/myeloma
or acute
leukemia/myeloid
malignancy
Allogeneic
(myeloablative)
Prospective
evaluation of day 100
survival, acute GVHD
and infection
complications
Elevated serum ferritin (≥1000ng/mL)
associated with
(i) increased mortality and decreased
o v e r a l ls u r v i v a l( P = .038 and .004,
resp.), (ii) increased acute GVHD and
increased blood stream infections
(P = .009 and .042, resp.)
Platzbecker
et al. 2008 [26]
172 patients with
MDS
Allogeneic
(myeloablative)
Retrospective
assessment of the
impact of transfusion
dependence on
patient prognosis
Transfusion dependence did not impact
directly on overall survival, but
transfusion burden, reﬂected by serum
ferritin, correlated with
(i) greater probability of acute GVHD
(P = .03)
(ii) inferior overall survival in patients
with serum ferritin levels of >1000ng/mL
(P = .03)
Kim et al. 2009
[27]
38 patients with
hematologic
malignancies
Allogeneic (reduced
intensity
conditioning)
Retrospective
assessment of
transplantation
outcome after RIST
Elevated serum ferritin
(≥1000ng/mL) resulted in
(i) reduced disease-free survival (35.8%
versus 80.6% in nonoverloaded
patients, P = .01);
(ii) reduced overall survival (27% versus
54.6% in the iron nonoverload group,
P = .03)
Kataoka et al.
2009 [28]
264 patients with a
variety of disorders,
(primarily acute
myeloge-
nous/lymphoblastic
leukemia, CML or
MDS)
Allogeneic
(myeloablative and
nonmyeloablative)
Retrospective
evaluation of 5-year
survival, nonrelapse
mortality, GVHD and
infection
S e r u mf e r r i t i nl e v e l so f
≥599ng/mL resulted in:
(i) lower overall survival, higher
nonrelapse mortality (P<. 001)
(ii) patients with high serum ferritin
levels were more likely to die of infection
and organ failure (P<. 01 and
<.019, resp.);
(iii) no signiﬁcant diﬀerence in
incidence of acute GVHD
Mahindra et al.
2009 [29]
64 patients with a
variety of disorders
(primarily AML,
nonHodgkin
lymphoma, or MDS)
Allogeneic
(nonmyeloablative)
Prospective
evaluation of 5-year
survival
(i) Pre-transplantation serum ferritin
levels of >1615ng/mL associated with
signiﬁcantly lower overall survival
(P = .012)
Lee et al. 2009
[30]
101 pediatric patients
with a variety of
disorders (primarily
acute lymphoblas-
tic/myeloid leukemia,
and aplastic anemia)
Allogeneic
(myeloablative)
Retrospective analysis
of 5-year survival
(i) Serum ferritin levels of >1000ng/mL
associated with reduced overall and
event-free survival (P = .001)Advances in Hematology 5
Table 2: Continued.
Patient type and
number Type of HSCT Outcome measures Key results
Mahindra et al.
2009 [31]
222 patients with
myeloid or lymphoid
leukemia,
nonHodgkin
lymphoma or MDS
Allogeneic
(myeloablative)
Retrospective
evaluation of survival
and GVHD
Pre-transplantation serum ferritin levels
of >1910ng/mL resulted in
(i) reduced overall and relapse-free
survival (P = .003 and .003, resp.);
(ii) reduced chronic GVHD (P = .019);
(iii) increased nonrelapse mortality
(P = .042)
AML: acute myeloid leukemia; CML: chronic myeloid leukemia;GVHD: graft-versus-host disease.
stream infections compared to those whose level was below
1000ng/ml [8]. Increased NTBI has been associated with an
increased risk of infection in patients with acute leukemia
and those who undergo myeloablative chemotherapy [32–
34].ElevatedNTBIinHSCTpatientshasbeenshowntosup-
portgrowthofStaphylococcusepidermidis[35].Retrospective
studies assessing pre-transplantation bone marrow iron
stores show that increased iron stores are a signiﬁcant risk
factor for severe infection, primarily invasive aspergillosis
[36, 37]. These data have been supported by assessment of
serum ferritin and liver iron concentration (LIC), where
elevated iron load is seen to be associated with higher
infection levels, particularly in patients who died after HSCT
[28, 38, 39].
GVHDremainsamajorcauseofmorbidityandmortality
after allogeneic HSCT [40]. While elevated pre-HSCT serum
ferritin levels have been associated with an increased inci-
dence of acute GVHD in some studies [8, 26], this has not
been a consistent ﬁnding, with others showing no eﬀect, or a
decrease in this event [24, 31] .I n d e e d ,ar e d u c t i o ni nG V H D
would be consistent with the known immunosuppressive
eﬀects of iron, but the equivocal ﬁndings to date indicate
the need for further investigation in prospective studies to
determine the association of iron overload and GVHD.
Another contributor to transplant-related mortality is
SOS, which occurs primarily as a result of endothelial and
hepatocyte damage due to conditioning regimen and is
associated with high morbidity and mortality [41–45]. The
impact of high iron levels on SOS has been investigated,
establishing serum ferritin levels of >1000ng/mL in the pre-
transplant period as a key risk factor for the subsequent
development of SOS [46–48]. Hepatic endothelial damage
induced by chemotherapy and potentiated by elevated LPI
afterconditioningcanbepostulatedasapossiblemechanism
mediating the increased risk of SOS in iron-overloaded
patients.
In summary, these data demonstrate that elevated
pre-transplantation serum ferritin levels have a signiﬁ-
cant impact on posttransplant complications and survival.
Indeed, pre-HSCT serum ferritin level has recently been
included in a prognostic score for patients with MDS or
acute leukemia undergoing allogeneic transplantation [49].
The score focuses on ﬁve variables: age, disease, stage
at transplantation, cytogenetics, and pre-transplant serum
ferritin (< or >2500ng/mL). It has been demonstrated that
pre-transplantation comorbidities, including dysfunction of
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Figure 4: Association of pre-transplantation serum ferritin levels
and morbidity [26]. Comorbidity index: 0 = low risk, 1 to 2 =
intermediate risk, 3 or more = high risk.
various organs (as categorized by the HSCT-comorbidity
index), have a profound impact on transplantation outcome
[50]. Subsequent assessment of whether serum ferritin levels
correlate with the HSCT-comorbidity index has shown that
iron overload is associated with a signiﬁcantly higher HSCT-
comorbidity index (Figure 4)[ 26].
5. Iron Overloadin the Post-HSCTPeriod
As data begin to accumulate, it is apparent that iron overload
can persist after HSCT, potentially for many years [51–53].
A recent analysis of data from 77 allogeneic HSCT patients
demonstrated that the elevated serum ferritin levels seen
in the pre-transplantation period increased further during
the posttransplant investigation period of 90 days [54]. In
addition, elevated serum ferritin levels have been observed
in patients who were independent of red cell transfusions
for several years after HSCT [55, 56]. In pediatric patients,
iron overload can decrease over time as a result of utilization
of storage iron for growth. However, a study of patients
who underwent HSCT for thalassemia demonstrated that
although a decrease in serum ferritin occurred in all
three risk groups (assigned prior to HSCT based on iron
overload), ferritin levels normalized only in the low risk
groups who were younger and had least iron overload
at time of HSCT. This shows that utilization of iron for
growth alone cannot normalize iron stores in moderate-to-
severelyiron-overloadedpediatricpatients[57].Inastudyof6 Advances in Hematology
Table 3: Published guidelines for managing iron overload in HSCT
recipients.
Source of
guidelines Focus of guidelines
Recommendations
for management of
iron load
Nagasaki
consensus group
(2005) [58]
Consensus
statement on iron
overload in MDS
(i) Candidates for
allograft could beneﬁt
from management of
iron load with
chelation therapy
European Group
for Blood and
Marrow
transplantation,
the Center for
International
Blood and Marrow
Transplant
Research and the
American Society
for Blood and
Marrow
transplantation
(2006) [59]
Long-term
survivors of HSCT
(i) Most long-term
survivors will have
some degree of iron
overload
(ii) LIC >7mgFe/g
dry weight (dw)
should be treated with
phlebotomy and/or
chelation therapy
MDS Foundation’s
Working Group on
Transfusional Iron
Overload (2008)
[60]
Consensus
statement on iron
overload in MDS
patients
(i) Allograft
candidates may
beneﬁt from chelation
therapy in order to
manage body iron
levels prior to
transplantation in
order to avoid
iron-related organ
dysfunction and
transplant-related
morbidity and
mortality
Canadian
consensus group
(2008) [61]
Iron overload in
MDS
(i) Consider iron
chelation in
transfusion-
dependent patients
who are candidates
for allogeneic HSCT
adult patients who had undergone HSCT for acute myeloid
leukemia, there was a drop in serum ferritin with time but
this decline was not statistically signiﬁcant [55].
The eﬀects of persistent iron overload on the long-term
morbidityofHSCTrecipients(particularlyasitrelatestolate
organ dysfunction) have not been investigated. These late
eﬀects may diﬀer between thalassemic and nonthalassemic
patients and may be related to the distribution of tissue
iron (parenchymal versus macrophage) in diﬀerent disease
states. Such studies will require long-term patient followup
as well as use of sensitive measurements for the evaluation
of cardiac, hepatic and endocrine dysfunction. Iron overload
is known to contribute to the etiology of liver dysfunction
chieﬂy manifesting as elevated transaminases, a common
chronic complication occurring in 50%–72% of patients
[62, 63]. Iron overload therefore can mimic exacerbation of
hepatic GVHD following HSCT, leading to unnecessary con-
tinuation or intensiﬁcation of immunosuppressive therapy
[64]. In a study assessing the role of liver biopsy in evaluating
the cause of elevated transaminases in post-HSCT patients,
33% of biopsies had evidence of iron overload and no other
pathologic ﬁndings [63]. Normalization in liver enzymes
has been demonstrated with phlebotomy and iron chelation
therapy [64, 65]. The role of persistent iron overload in
infections that occur late after HSCT, particularly in patients
with chronic GVHD requires further investigation.
6. PracticalPatient Management
Although no data from controlled trials that document a
survival impact of managing iron overload in MDS patients
prior to undergoing HSCT are currently available, recent
MDS guidelines highlight the need for management of
iron load in HSCT candidates. The rationale for these
recommendations is the particularly strong adverse survival
impact of pre-HSCT iron overload in these patients. These
guidelines are summarized in Table 3 [58–61].
6.1. Assessing Iron Load in the HSCT Patient. Ferritin is a
cellular iron storage protein that maintains iron in a soluble
and nontoxic form. Under normal conditions, ferritin levels
in the serum are low, but steadily increase in conditions of
iron overload. Therefore, assessment of serum ferritin levels
serves as a simple and widely used surrogate marker for
body iron load. Serum ferritin levels are, however, subject
to natural ﬂuctuation and can also be greatly aﬀected by a
rangeofconditionsthatareparticularlyrelevantintheHSCT
patient.Theseincludeinﬂammation,liverdamage,infection,
and GVHD, all of which can result in elevated serum
ferritin levels and, therefore, potential overestimation of iron
load. Serial serum ferritin measurements can compensate
for potential ﬂuctuations to some extent and should be
performed to establish a picture of iron overload over time.
As 90% of excess iron is deposited in the liver, assessment
of LIC provides an accurate measure of whole-body iron
levels [66]. Measurement of LIC by biopsy is the validated
reference standard but increasingly noninvasive magnetic
resonance imaging (MRI) techniques are replacing this
approach as the technology becomes more widely available
[67]. An additional advantage of MRI is its ability to
measure cardiac iron, which does not correlate with serum
ferritin or hepatic iron. Cardiac iron deposition, although
uncommon in nonthalassemic patients can occur in certain
patients with MDS [68–70]. As with evaluation of serum
ferritin, thresholds for LIC levels have been determined
primarily from thalassemia populations, indicating that LIC
levels of >7mgFe/g dry weight present an increased risk
of complications [66, 71–73]. Threshold levels speciﬁc to
recipients of HSCT have not been investigated, but could
diﬀer signiﬁcantly from other settings and require further
investigation.
A signiﬁcant correlation between serum ferritin and
LIC has been established in regularly transfused patientsAdvances in Hematology 7
with thalassemia major [71, 74]. However, in patients with
thalassemia intermedia assessment of serum ferritin levels
hasbeenshowntosigniﬁcantlyunderestimatebodyironload
[75]. As serum ferritin predominantly reﬂects macrophage
iron, such may be the case with certain patients with MDS
who have ineﬀective erythropoiesis leading to increased iron
absorption from the gut and increased parenchymal iron.
Disease-speciﬁc considerations and acute complications are
likely to present a complex environment in which to
determine the relationships between serum ferritin, LIC, and
parenchymal iron in a particular HSCT patient. Studies have
determined the correlation between LIC assessed by MRI
a n ds e r u mf e r r i t i nl e v e l si nl o n g - t e r ms u r v i v o r so fH S C T .
In one study of 65 patients who had survived a median of
8.8 years after HSCT, there was a good correlation between
LIC and number of red blood cell transfusions (r = .84) but
only a moderate correlation between LIC and serum ferritin
(r = .55) [76]. Two other studies that have examined this
issue showed only a modest correlation (ρ = .47) or no
correlation at all between serum ferritin and LIC measured
by MRI [77, 78]. Thus, serum ferritin may have limited
u s e f u l n e s sa sam a r k e ro fi r o no v e r l o a di ns u rvi v o r so fH S C T
and this may be due to acute inﬂammatory states or hepatic
inﬂammation in many of these patients.
6.2. Management of Iron Overload in the HSCT Patient
6.2.1. Timing of Intervention. A key factor in dealing with
iron overload in the HSCT recipient is the timing of inter-
vention with relation to HSCT. This depends on whether the
m a j o rg o a li st or e d u c et i s s u ei r o ns t o r e so rt ot e m p o r a r i l y
lower NTBI and LPI in the period from conditioning to
engraftment. The three possible opportunities to intervene
are the following.
(1) Prior to HSCT (before initiation of conditioning):
since HSCT often has to be performed quickly in
patients with conditions, such as acute leukemia,
an opportunity to achieve negative iron balance in
transfusion-dependent patients prior to HSCT may
be possible only in certain settings, for example
intermediate risk MDS where some delay in HSCT
is acceptable. Since the impact of serum ferritin
on overall survival persists when examined as a
continuous variable, it appears that patients would
beneﬁt from undergoing HSCT at the lowest possible
body iron burden. Randomized prospective studies
of immediate HSCT versus HSCT after adequate
chelation are feasible in MDS and will be required
to determine the role of chelation after a decision to
proceed to HSCT has been made.
(2) Immediate peritransplant period (from start of con-
ditioning until engraftment):a sN T B Il e v e l si n c r e a s e
immediately after initiating conditioning and remain
elevated at least until engraftment, iron chelation in
this HSCT phase could limit the eﬀects of high NTBI
levels and oﬀer potential beneﬁts in terms of reduced
riskofinfectionandSOSwithoutloweringtotalbody
iron. Prospective studies are needed to demonstrate
the beneﬁt of this strategy. The ideal chelator for
this phase would be one that does not release bound
iron to microbes (unlike deferoxamine, Desferal),
but which can be administered intravenously (unlike
deferiprone (Ferriprox) and deferasirox (Exjade)).
Moreover, chelators considered for use during this
phase of HSCT should not have deleterious eﬀects on
other HSCT outcomes like engraftment and immune
reconstitution or major interactions with immuno-
suppressive agents. Novel iron-binding agents such
as apotransferrin have potential for use during this
period but require further evaluation [35].
(3) Latepost-HSCTperiod(afterDay+100):inlong-term
adult survivors of HSCT, excess body iron can persist
and is generally poorly managed. A comprehensive
strategyconsideringpatientdiagnosis,comorbidities,
and tissue iron distribution appears to be necessary
to guide proper management. Awareness of iron
overload and eﬀective management in this period
has potential to improve long-term patient outcome.
Practical treatment options in this phase include
phlebotomy or an oral chelator like deferasirox as
discussed in detail later.
6.3. Therapeutic Options
6.3.1. Phlebotomy. Phlebotomy is a simple and eﬀective
approach to remove excess tissue iron. For obvious reasons,
its use will be limited to patients with good graft function,
platelet engfaftment and venous access. Compliance with
treatment is usually good and it is a relatively inexpensive
procedure to perform. While data in the HSCT population
are limited, it has been shown that phlebotomy (alone or
with erythropoietin (EPO) support) can eﬀectively reduce
serum ferritin levels [64, 76, 79, 80]. A similar program
of phlebotomy combined with EPO has been shown to
normalize liver enzymes and reduce serum ferritin levels
following transplantation [64]. It has been shown that the
red cell regeneration induced by EPO is more pronounced
in donors with iron overload than in those with normal
iron levels [81]. Following HSCT, restoration of normal
erythropoiesis allows phlebotomy to be performed and a
study in posttransplantation thalassemia patients has shown
thepotential ofthis approach[82].Sincemanyeﬀectsof iron
overloadappeartobemediatedbyNTBI,itwillbeimportant
to determine how quickly phlebotomy can normalize NTBI
in patients with elevated levels.
6.4. Iron Chelation Therapy. The iron-chelating agent defer-
oxamine has been available for many years and is the
reference standard against which newer therapies are com-
pared. Its use in the HSCT patient is complicated by
the very short half life and the ability of deferoxamine
to release iron to bacteria and fungi [83, 84]. In one of
the earliest studies to evaluate chelation therapy in HSCT,
continuous intravenous deferoxamine was administered in
two diﬀerent schedules from day −9t od a y+ 6 0a f t e r
HSCT in patients with thalassemia, eﬀectively reducing8 Advances in Hematology
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Figure 5: Eﬀe c to fm a n a g e m e n to fi r o nl e v e l sw i t hi r o nc h e l a t i o n
therapy on outcome in pediatric HSCT patients [30]. Patients
receiving iron chelation (IC) therapy to reduce high iron load
demonstrated survival levels similar to patients with low serum
ferritin (F) levels at transplantation (N = 101).
serum ferritin levels at 6 months without detrimental eﬀect
[85]. In particular, no adverse eﬀects on engraftment or
infection risk were noted. Other studies in thalassemia have
provided support for the safety and value of chelation
therapy started as early as 3 months after HSCT in lowering
serum ferritin and hepatic iron [65, 80]. More recently
it has been demonstrated in a study of pediatric patients
undergoing allogeneic HSCT that pre-transplantation serum
ferritin levels of >1000ng/mL were associated with lower
survival. Meanwhile, iron-overloaded patients treated before
HSCT with deferoxamine or deferasirox to reduce serum
ferritin levels to <1000ng/mL showed no diﬀerences in
complications and survival compared with patients whose
serum ferritin levels were below 1000ng/mL before HSCT
(Figure 5)[ 30]. This study provides proof of principle for
the value of iron chelation therapy prior to HSCT in order
to reduce the complications of HSCT and improve patient
outcomes.
Whilst studies of deferoxamine use in the HSCT setting
conﬁrm the value of eﬀective management of iron overload,
a key limitation is the demanding regimen of frequent,
prolonged infusions (40mg/kg infused 8–12 hours/day at
least 5 days per week). A development in iron chelation
therapy came with the availability of the ﬁrst oral therapy,
deferiprone, a thrice-daily formulation that was approved
in Europe in 1999 for the treatment of adult patients
with thalassemia as second-line therapy when deferoxamine
therapyiscontraindicatedorinadequate.However,thisagent
has not been investigated in the HSCT setting and is not
available in the USA or Canada. Due to the serious nature of
agranulocytosis that can occur with the use of deferiprone,
close monitoring is required for all patients [86–88].
More recently, a once-daily oral therapy, deferasirox,
has been licensed in many countries around the world,
having been investigated in a wide range of patient types,
primarily those with secondary iron overload as a result of
chronic red cell transfusions [89–91]. A particular advantage
of deferasirox due to its long half-life is its ability to bind
LPI on a round-the-clock basis. The ability of deferasirox
to normalize LPI by 3 months has been demonstrated in
patients with myelodysplasia [92]. Studies are now being
conducted in the HSCT setting to determine the eﬃcacy
and impact of deferasirox on outcomes in this speciﬁc
patient group. The common adverse events associated with
deferasirox therapy, such as gastrointestinal discomfort and
serum creatinine elevation, may, however, overlap with
common acute side eﬀects seen after allogeneic transplant,
making investigation of deferasirox in early HSCT diﬃcult
[54, 93]. In addition, the renal toxicity of deferasirox when
usedinconjunctionwithcyclosporineortacrolimusrequires
further investigation. Lower doses of deferasirox may be
eﬀective in reducing iron burden in patients who have been
rendered transfusion-independent by HSCT.
7. Conclusions
In recent years, investigation of the association between
iron overload and HSCT outcomes has clearly highlighted
the adverse impact of elevated serum ferritin levels prior
to HSCT on overall survival and complications. While the
question of whether a high iron burden contributes directly
to poor patient outcome or whether serum ferritin levels act
as a surrogate marker for patient prognosis requires further
evaluation in prospective multicenter studies, there appears
to be no doubt that iron overload can be considered as an
independentadverseprognosticfactorinallogeneicHSCT,at
least in patients with thalassemia, myelodysplasia, and acute
leukemia.
Thedatapresentedhighlighttheneedtodevelopeﬀective
management strategies in the pre-, peri-, and posttrans-
plantation phases to reduce complications and improve
survival. Studies using MRI assessment of tissue iron burden
and measurement of LPI at various phases of HSCT and
correlating these measures with outcomes will be necessary
to fully deﬁne the pathophysiology of iron overload in the
transplant patient. It is likely that in an individual patient,
treatment will require tailoring based on factors such as
the nature of the underlying disease, comorbidities, and the
distribution of tissue iron.
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